KeyBanc analyst Jeffrey Hammond maintained a Buy rating on Colfax (NYSE:CFX) Corp on Wednesday, setting a price target of $44, which is approximately 26.44% above the present share price of $34.8.
Hammond expects Colfax Corp to post earnings per share (EPS) of $0.10 for the fourth quarter of 2020.
The current consensus among 6 TipRanks analysts is for a Moderate Buy rating of shares in Colfax, with an average price target of $36.33.
The analysts price targets range from a high of $44 to a low of $30.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $805.93 million and a net profit of $66.06 million. The company's market cap is $4.12 billion.
According to TipRanks.com, KeyBanc analyst Jeffrey Hammond is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 10.4% and a 59.52% success rate.
Colfax Corp. operates as a diversified technology company that provides orthopedic care and fabrication technology products and services to customers. The firm operates its business through the following segments: Medical Technology; and Fabrication Technology. The Medical Technology segment develops, manufactures and distributes medical devices with a broad range of products used for rehabilitation, pain management and physical therapy. The Fabrication Technology develops, manufactures, and supplies consumable products and equipment. The company was founded by Mitchell P. Rales and Steven M. Rales in 1995 and is headquartered in Annapolis Junction, MD.